Climb Bio said its cash runway reaches into the second half of 2028, inclusive of all pivotal startup and CMC spend, as it moves toward pivotal studies. For its BUDO program, enrollment in the 600 dose is complete and the 1,000 dose is enrolling.
CLYM · Climb Bio, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 55%
- Last earnings
- Sep 3, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Aug 2021 to Nov 2026
Up next
Latest documents
Climb Bio is advancing BUDO toward a phase three PMN study and its APRIL antibody toward phase three IgA nephropathy development, with cash runway into the second half of 2028.
Climb Bio, Inc. launched an automatic shelf registration allowing future sales of multiple securities, with offering amounts and terms to be determined.
Budoprutug produced deeper peripheral B-cell depletion at 600 mg, with mean suppression of 98% at Week 4. Climb Bio, Inc. reported $227.6 million in cash and marketable securities on September 30, 2026, funding operations into the second half of 2028.
Climb Bio began dosing in the NAVIGATE-2 Phase 2 trial for IgAN. Budoprutug’s 200 mg cohort demonstrated B-cell depletion, PLA2R antibody reductions, and immunologic remission at Week 12.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Complete platelet response | 33% | Phase 1b Cohort 1 (6 participants) | — |
| Durable platelet response | 67% | Phase 1b Cohort 1 (6 participants) | — |
| Free APRIL suppression sustained through 12 weeks | 90% | 12 weeks following a single SC dose of ≥480 mg | — |
| Fully diluted shares outstanding | 81.3M | As of Oct 30, 2026 | — |
| Gd-IgA1 reduction at 12 weeks | 70% | 12 weeks following a single 800 mg dose | — |
| Half-life | 33 | Phase 1 healthy volunteers (CLYM116) | — |
| IgA reduction | 60% | Week 12 after a single 800 mg dose | — |
| Mean B-cell depletion | 90% | Week 4 | — |
| Mean B-cell reduction | 84% | Week 12 (100 mg cohort) | — |
| Mean increase in platelet count from baseline | 111K | Week 24 | — |
| Participants enrolled in budoprutug SLE Phase 1b trial | 17 | As of the October 7, 2026 data cutoff | — |
| Participants in ITP safety analysis population | 15 | Initial Phase 1b data cut | — |
| Participants who received CLYM116 | 67 | Pooled Australia and China Phase 1 studies | — |
| Participants with any TEAE | 12 | SLE Phase 1b (18 participants dosed) | — |
| Response among participants with prior rituximab | 75% | Phase 1b Cohort 1 (4 participants with prior rituximab) | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLYM
this stock
Climb Bio, Inc.
|
$545.09M | +132.0% | — | — | 18.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 36
Climb Bio said its cash runway reaches into the second half of 2028, inclusive of all pivotal startup and CMC spend, as it moves toward pivotal studies. For its BUDO program, enrollment in the 600 dose is complete and the 1,000 dose is enrolling.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLYM | -14.6% | -12.0% | -21.4% | -9.5% | +132.0% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -9.2% | -5.7% | -15.7% | -4.2% | +127.0% |